Use of GLP-1 analogs in the treatment of multiple sclerosis

Use of GLP-1 analogs in the treatment of multiple sclerosis

Moved to EU CTIS registryPhase 2Relapsing MS2019-003001-94

What was tested

Treatment tested

  • Trulicity 0,75 mg injekčný roztok naplnený v injekčnom pere

What it measured

Main measures

  • To determine the effect of GLP-1 receptor agonist on chronic axonal damage and neurodegeneration in patients with MS

Other measures (1)

  • To determine the effect of GLP-1 receptor agonist on insulin sensitivity in patients with MS

Papers

    Loading reviews and guidelines…

    History

    1. In scope changed from true to false

    1. Started

      Sept 2019

    Assembled by software from public sources.